Latest Breaking News On - Efficacy across - Page 1 : comparemela.com

Intra-Cellular Therapies Highlights Data Presentations at the American Society of Clinical

NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders,

United statesCameron radinovic lee rothJuan sanchezCellular therapies incBurns mcclellan incExchange commissionAmerican society of clinical psychopharmacologyCorporate communicationsCellular therapiesAmerican societyClinical psychopharmacologyAnnual meetingPatients with major depressive disorderBipolar disorderAnxious distressMajor depressive disorder

Investegate |NOVARTIS AG CHF0 50(REGD) Announcements | NOVARTIS AG CHF0 50(REGD): New Kisqali® data shows consistent overall survival benefit across genomic and clinical subtypes of interest in HR+/HER2- metastatic breast cancer

Investegate |NOVARTIS AG CHF0 50(REGD) Announcements | NOVARTIS AG CHF0 50(REGD): New Kisqali® data shows consistent overall survival benefit across genomic and clinical subtypes of interest in HR+/HER2- metastatic breast cancer
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.

San antonioUnited statesNew jerseyComunidad autonoma de catalunaEast hanoverIsabella zinckThomas hungerbuehlerSusanne schaffertAshley bufordClin oncSamir shahParag mahantiJulie masowSloan simpsonAleix pratAlina levchuk

Novartis Pharma AG: New Kisqali data shows consistent overall survival benefit across genomic and clinical subtypes of interest in HR+/HER2- metastatic breast cancer

Data from the MONALEESA Phase III program provide further evidence of the unique profile of Kisqali, the CDK4/6 inhibitor with the longest reported median overall survival (OS) in HR+/HER2- metastatic

San antonioUnited statesNew jerseyComunidad autonoma de catalunaEast hanoverIsabella zinckThomas hungerbuehlerSusanne schaffertAshley bufordClin oncSamir shahParag mahantiJulie masowSloan simpsonAleix pratAlina levchuk

New Kisqali® data shows consistent overall survival benefit across genomic and clinical subtypes of interest in HR+/HER2- metastatic breast cancer

/PRNewswire/ Novartis today announced new Kisqali® (ribociclib) data demonstrating a consistent overall survival (OS) benefit with Kisqali plus endocrine.

San antonioUnited statesNew jerseyComunidad autonoma de catalunaEast hanoverJulie masowJamie bennettSloan simpsonSusanne schaffertAleix pratClin oncPrnewswire novartisAmerican society of clinical oncologyEuropean society of medical oncologyTranslational research in oncologyHead of the translational genomics group

New Kisqali® data shows consistent overall survival benefit across genomic and clinical subtypes of interest in HR+/HER2- metastatic breast cancer

/PRNewswire/ Novartis today announced new Kisqali® (ribociclib) data demonstrating a consistent overall survival (OS) benefit with Kisqali plus endocrine.

San antonioUnited statesNew jerseyComunidad autonoma de catalunaEast hanoverJulie masowJamie bennettSloan simpsonSusanne schaffertAleix pratClin oncPrnewswire novartisAmerican society of clinical oncologyEuropean society of medical oncologyTranslational research in oncologyHead of the translational genomics group